AR017973A1 - Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo - Google Patents
Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpoInfo
- Publication number
- AR017973A1 AR017973A1 ARP990100239A ARP990100239A AR017973A1 AR 017973 A1 AR017973 A1 AR 017973A1 AR P990100239 A ARP990100239 A AR P990100239A AR P990100239 A ARP990100239 A AR P990100239A AR 017973 A1 AR017973 A1 AR 017973A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- antibody
- storage
- formulations
- present
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 11
- 239000000203 mixture Substances 0.000 title abstract 11
- 238000002360 preparation method Methods 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 238000003860 storage Methods 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- 239000007979 citrate buffer Substances 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 229940072221 immunoglobulins Drugs 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000013618 particulate matter Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003892 spreading Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9800170A SE9800170D0 (sv) | 1998-01-22 | 1998-01-22 | Formulation |
| SE9800766A SE9800766D0 (sv) | 1998-03-09 | 1998-03-09 | Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017973A1 true AR017973A1 (es) | 2001-10-24 |
Family
ID=26663196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100239A AR017973A1 (es) | 1998-01-22 | 1999-01-21 | Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR017973A1 (fr) |
| AU (1) | AU2444899A (fr) |
| WO (1) | WO1999037329A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2601882T5 (es) | 1999-04-09 | 2021-06-07 | Kyowa Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US20030124119A1 (en) * | 1999-12-28 | 2003-07-03 | Tadao Yamazaki | Stable antibody compositions and injection preparations |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| WO2005005636A1 (fr) | 2003-07-15 | 2005-01-20 | Chugai Seiyaku Kabushiki Kaisha | Production d'igm par une cellule transformee et procede de quantification de cette derniere |
| HUE026793T2 (en) * | 2003-10-01 | 2016-07-28 | Kyowa Hakko Kirin Co Ltd | A method for stabilizing an antibody and a stabilized solution-type antibody preparation |
| WO2005035573A1 (fr) * | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Methode de stabilisation de solution proteinique |
| EP1688432B1 (fr) | 2003-10-09 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Solution stabilisee a concentration elevee en igm |
| US20070184050A1 (en) * | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
| AU2005226736B2 (en) * | 2004-03-24 | 2009-11-26 | Abbvie Biotherapeutics Inc. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| NZ571757A (en) * | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| WO2013103783A1 (fr) * | 2012-01-04 | 2013-07-11 | Sanofi Us | Anticorps murins il-13 |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| PE20150964A1 (es) | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011298A1 (fr) * | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Formule de reactifs contenant des anticorps |
| JPH04504253A (ja) * | 1989-03-27 | 1992-07-30 | セントカー・インコーポレーテツド | ＩｇＭ抗体の安定化のための配合物 |
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| CA2507749C (fr) * | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
| GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
-
1999
- 1999-01-15 AU AU24448/99A patent/AU2444899A/en not_active Abandoned
- 1999-01-15 WO PCT/SE1999/000049 patent/WO1999037329A1/fr not_active Ceased
- 1999-01-21 AR ARP990100239A patent/AR017973A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2444899A (en) | 1999-08-09 |
| WO1999037329A1 (fr) | 1999-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017973A1 (es) | Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo | |
| KR950014915B1 (ko) | 탈시알로당단백-포함화합물 | |
| CA1329543C (fr) | Formulation a base d'hormone de croissance humaine | |
| AU608584B2 (en) | Stable interferon complexes | |
| Gresser et al. | Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice | |
| JPH03504967A (ja) | 血液脳関門を介しての神経ペプチド運搬のためのキメラ性ペプチド | |
| JPH03502197A (ja) | 新規な抗炎症剤 | |
| PT88626B (pt) | Processo para a preparacao de um factor de crescimento polipeptidico proveniente de leite | |
| AR052198A1 (es) | Formulaciones anticuerpo anti a beta | |
| JPH01500901A (ja) | キメラペプチド及びそれを含む組成物 | |
| JPH07506113A (ja) | 前立腺癌，胃癌および乳癌に関連する腫瘍を抑制するための医薬製剤 | |
| Tsutsumi et al. | PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency | |
| KR101363237B1 (ko) | 증강된 비율의 감마 인터페론 및 알파 인터페론을 포함하는안정화된 제형 | |
| US7147849B2 (en) | Pharmaceutical formulation | |
| KR900015749A (ko) | 인터루킨-1제형 | |
| ES2329204T3 (es) | Composicion antiviral que comprende interferon en forma de gotas nasales. | |
| ES2908141T3 (es) | Formulaciones y dosis de cannabinoides | |
| DK1173476T3 (da) | Funktionelle sojabönneproteiner | |
| JPH06247872A (ja) | 高濃度ｔｃｆ製剤 | |
| JPH0640938A (ja) | Ｈｇｆ含有製剤 | |
| JPH0441421A (ja) | 肺吸収組成物 | |
| JPS6360940A (ja) | 白内障の予防または治療剤 | |
| US5534251A (en) | Stabilized il-1α medicinal composition | |
| CN101011572A (zh) | 一种重组人甲状旁腺激素(1－84)药物组合物及其制备方法 | |
| ES2226326T3 (es) | Hormona de crecimiento humana para estimular la hematopoyesis y la reconstitucion del sistema inmune despues del trasplante de celulas madre hematopoyeticas en seres humanos. |